Deliver a professional moderate to severe allergic rhinitis service through Scripter's structured consultation pathway. Supply: Azelastine with fluticasone propionate nasal spray (Dymista).

Book a demo Browse all PGDs

Illustration: Moderate to severe allergic rhinitis

What is Azelastine / fluticasone (Dymista)?

Dymista combines a topical antihistamine (azelastine) with an intranasal corticosteroid (fluticasone) in one spray, treating both the immediate histamine response and the underlying inflammation. It outperforms either component alone in moderate to severe rhinitis.

The condition it treats

Moderate to severe allergic rhinitis is rhinitis that keeps interfering with sleep, work or school despite single-agent treatment. Stepping up to combination therapy is the recognised next move before considering referral.

How the service runs on Scripter

Patients book online, complete the pre-consultation questionnaire, and the guided pathway walks the practitioner through the moderate to severe allergic rhinitis consultation with the screening and counselling steps built in. The supply decision, the record and any GP notification are produced in the same flow, documented against the exact protocol version in force.

Training and eligibility requirements.

Who can deliver this service, and who it can be delivered to. The governing PGD document defines the definitive inclusion, exclusion and supply criteria; the Scripter consultation pathway enforces them, and every consultation is documented against the protocol version it ran under.

Practitioner training

✓Registered healthcare professional from a profession authorised to supply under PGDs (Schedule 16, Part 4 of the Human Medicines Regulations 2012), such as a pharmacist, nurse, paramedic or physiotherapist, with current registration with their professional regulator

✓Practising from premises suitable for the service, such as registered pharmacy premises or a registered clinic

✓Assessed clinical competency for this service, declared and reviewed as part of PGD authorisation

✓Sign-off against the current version of this PGD in Scripter before first supply; sign-offs expire automatically when the protocol is updated, and the platform notifies everyone affected

✓In-date basic life support and safeguarding training

✓Indemnity arrangements covering the service

Patient eligibility

✓Patients within the governing PGD's age range whose symptoms persist despite a single-agent spray or antihistamine

✓Nasal red flags (unilateral blockage, bleeding, crusting) referred

✓Pregnancy and breastfeeding screened per the governing PGD

✓Technique and regular-use counselling completed; steroid sprays work with daily use, not on demand

Azelastine / fluticasone (Dymista) PGD questions

When is Dymista the right step?+

When a steroid spray or antihistamine alone has not controlled symptoms after proper regular use; the consultation checks technique and adherence first, because poor technique masquerades as treatment failure.

How long until full effect?+

Relief begins within days but the anti-inflammatory effect builds over one to two weeks of daily use; the pathway sets that expectation explicitly.

Is long-term use safe?+

Intranasal steroids at licensed doses have a good long-term safety record; the review point in the pathway keeps seasonal use purposeful rather than perpetual.

More allergic rhinitis PGDs.

Related protocols in the same category, all delivered through the same platform.

Azelastine nasal spray

Allergic rhinitis

View PGD

Run a moderate to severe allergic rhinitis service without the paperwork.

See the consultation pathway, the sign-off tracking and the record it produces in a free 30-minute demo.

Book a demo Contact us

Built for pharmacists, by pharmacists.